Sitagliptin: an oral agent for glucose control.

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Diseases

Background:

• Type 2 diabetes mellitus (T2DM) is a global health concern requiring effective glucose-lowering agents.
• Current T2DM treatments have limitations including side effects and administration challenges.
• Incretin hormones play a crucial role in glucose homeostasis, making their modulation a therapeutic target.

Purpose of the Study:

• To introduce sitagliptin, a novel oral dipeptidyl peptidase (DPP)-4 inhibitor for T2DM management.
• To elucidate the mechanism of action of sitagliptin in enhancing incretin activity.
• To review the efficacy, safety, and unique advantages of sitagliptin compared to existing antidiabetic drugs.

Main Methods:

• Sitagliptin selectively inhibits dipeptidyl peptidase (DPP)-4.
• This inhibition preserves and enhances the activity of incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
• Clinical studies evaluated sitagliptin's impact on glycemic control, including HbA1c, postprandial, and fasting glucose levels.

Main Results:

• Sitagliptin significantly reduces hemoglobin A1c (HbA1c), postprandial glucose excursion, and fasting plasma glucose.
• The drug is orally administered and demonstrates a low incidence of hypoglycemia, comparable to placebo.
• Adverse events are generally mild (e.g., headache, upper respiratory infection) and it does not cause weight gain.

Conclusions:

• Sitagliptin represents a new class of oral antihyperglycemics (DPP-4 inhibitors) for T2DM.
• Its efficacy in improving glycemic control, favorable safety profile, and oral administration offer distinct advantages.
• Preliminary animal data suggest potential roles in beta-cell protection, warranting further investigation in humans.